- Home
- SCWO vs CHRS Comparison
SCWO vs CHRS Comparison
Compare SCWO & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCWO
- CHRS
- Stock Information
- Founded
- SCWO 2021
- CHRS 2010
- Country
- SCWO United States
- CHRS United States
- Employees
- SCWO N/A
- CHRS N/A
- Industry
- SCWO Environmental Services
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SCWO Utilities
- CHRS Health Care
- Exchange
- SCWO Nasdaq
- CHRS Nasdaq
- Market Cap
- SCWO 186.8M
- CHRS 191.3M
- IPO Year
- SCWO N/A
- CHRS 2014
- Fundamental
- Price
- SCWO $0.64
- CHRS $1.51
- Analyst Decision
- SCWO
- CHRS Strong Buy
- Analyst Count
- SCWO 0
- CHRS 4
- Target Price
- SCWO N/A
- CHRS $5.38
- AVG Volume (30 Days)
- SCWO 378.3K
- CHRS 2.3M
- Earning Date
- SCWO 11-13-2024
- CHRS 11-06-2024
- Dividend Yield
- SCWO N/A
- CHRS N/A
- EPS Growth
- SCWO N/A
- CHRS N/A
- EPS
- SCWO N/A
- CHRS N/A
- Revenue
- SCWO $313,930.00
- CHRS $304,340,000.00
- Revenue This Year
- SCWO N/A
- CHRS $2.47
- Revenue Next Year
- SCWO $5,180.00
- CHRS N/A
- P/E Ratio
- SCWO N/A
- CHRS N/A
- Revenue Growth
- SCWO N/A
- CHRS 44.19
- 52 Week Low
- SCWO $0.54
- CHRS $0.66
- 52 Week High
- SCWO $1.99
- CHRS $2.97
- Technical
- Relative Strength Index (RSI)
- SCWO 30.61
- CHRS 55.21
- Support Level
- SCWO $0.54
- CHRS $1.44
- Resistance Level
- SCWO $0.74
- CHRS $1.77
- Average True Range (ATR)
- SCWO 0.06
- CHRS 0.13
- MACD
- SCWO 0.01
- CHRS -0.02
- Stochastic Oscillator
- SCWO 44.86
- CHRS 50.00
About SCWO 374Water Inc.
374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The business activities of the company include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.